CFTR and cystic fibrosis: In the US, modulators are now available to over 90% of children and adults with CF over the age of 2 who have one or more responsive CFTR genetic variants, including the most common CFTR variant, F508del [4,5]; ivacaftor was recently approved for infants with responsive CFTR variants as young as one month of age [6].